Business Wire

TII

29.3.2021 15:33:09 CEST | Business Wire | Press release

Share
Abu Dhabi’s Technology Innovation Institute Unveils First Post-Quantum Cryptography Library in UAE

Technology Innovation Institute (TII), the applied research pillar of Abu Dhabi’s Advanced Technology Research Council (ATRC), today announced that its Cryptography Research Centre (CRC) has launched the first Post-Quantum Cryptography (PQC) software library in the UAE.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210329005486/en/

The library will advance the cryptographic and security capabilities of the emirate of Abu Dhabi and the broader UAE. International and Emirati researchers at Cryptography Research Centre, one of Technology Innovation Institute’s initial seven dedicated research centres, have developed the PQC library, a software library written in the C general-purpose programming language that supports a wide variety of computer architectures and operating systems. A corresponding hardware FPGA-based implementation has also been developed. The library, designed to guard against attacks by quantum computers, has been already integrated in several secure communication products.

The library is a collection of algorithms to safeguard confidential data and information. With the rise of quantum computers, classic cryptographic algorithms (in particular, public key / asymmetric algorithms) are no longer sufficient to ensure secure data storage and secure digital communication. To address the demand for an advanced level of security that cannot be compromised even on sophisticated quantum computers, cryptographers are now engaged in developing PQC algorithms.

Cryptography Research Centre employs and collaborates with scientists in multiple cryptography fields such as post-quantum cryptography, hardware-based cryptography, lightweight cryptography, cryptanalysis, cryptographic protocols, and cloud encryption schemes, amongst others. The Centre is also among the few internationally that brings together theoretical and applied cryptographers in a research-oriented setting. The cryptographers collaborate on breakthrough research projects that lead to innovative outcomes.

Speaking on the announcement, His Excellency Faisal Al Bannai, Secretary General of the Advanced Technology Research Council (ATRC), said: “The United Arab Emirates is now in the same league of countries that possess advanced digital data security capabilities. Our researchers have worked hard to make this revolutionary project a reality. To meet the growing level of sophistication in the world of data, systems and network security, we are currently engaged in many more such ventures for the future. Our researchers are shaping the building blocks of advanced cryptographic and cryptanalytic solutions that enable superior data confidentiality, integrity, authentication, non-repudiation, and privacy.”

Dr Najwa Aaraj, Chief Researcher at the Cryptography Research Centre, said: “Quantum computing capabilities are a potential threat to data security. This fact underscores the importance of the launch of the UAE’s first post-quantum cryptography library to guard against quantum computer attacks. The first release of the library has already been integrated in several secure communication products with advanced cryptographic protocols. Such a library serves as the foundation of any security application or product in development today that integrates public-key cryptography functionality. We will continue to develop the PQC library through incorporating more schemes.”

Technology Innovation Institute is a pioneering global research and development centre that focuses on applied research and new-age technology capabilities. The Institute has seven initial dedicated research centres in quantum, autonomous robotics, cryptography, advanced materials, digital security, directed energy and secure systems. By working with exceptional talent, universities, research institutions and industry partners from all over the world, the Institute connects an intellectual community and contributes to building an R&D ecosystem in Abu Dhabi and the UAE. The Institute reinforces Abu Dhabi and the UAE’s status as a global hub for innovation and contributes to the broader development of the knowledge-based economy.

For more information about Technology Innovation Institute (TII), visit www.tii.ae

*Source: AETOSWire

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

IEO and Laife Reply Join Forces to Digitalise the Biobank Through Artificial Intelligence10.2.2026 10:00:00 CET | Press release

The two partners launch “Bianca”, the first large-scale digitalisation initiative in Italy focused on histopathological samples, aimed at training AI algorithms to support pathologists’ diagnostic activities. The Pathology Division of the European Institute of Oncology (IEO) and Laife Reply, the Reply Group company specialised in AI and Big Data solutions for the healthcare sector, have entered into a collaboration to develop Bianca, the first project in Italy aimed at creating an AI-based digital biobank designed as an integral part of clinical diagnostic practice. The initiative is part of a broader technological innovation journey that structurally integrates research and development into routine diagnostic processes in pathology, transforming the traditional histopathological sample workflow into an end-to-end digital ecosystem. The complete digitalisation of histopathological and molecular diagnostic workflows aims to make analysis more efficient, scalable and reproducible, laying

OPEX® Corporation Introduces the Velo™ Series of Premium Desktop and High Production Document Scanners10.2.2026 10:00:00 CET | Press release

OPEX® Corporation, a global leader in Next Generation Automation providing innovative solutions for warehouse, document and mail automation, has announced the launch of its Velo™ Series powered by InoTec, a new class of premium desktop and free standing high production scanners. The OPEX Velo scanners are engineered to deliver exceptional performance, reliability and image quality and offer industry-standard TWAIN/ISIS connectivity to help simplify deployment into existing capture environments. These state-of-the-art scanners are ideal for service bureaus, government agencies, healthcare providers and enterprise capture operations. “The Velo Series powered by InoTec introduces an entirely new class of scanners to the OPEX portfolio, expanding the options available to both our current customers and organizations considering OPEX for the first time,” said Dann Worrell, President, Document and Mail Automation, OPEX. “By broadening our offerings, we can better align the right solution with

New ZOLL Zenix Monitor/Defibrillator Receives MDR Approval10.2.2026 10:00:00 CET | Press release

ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that Zenix®, the company’s most clinically advanced and easy-to-use professional monitor/defibrillator, is approved under the European Union (EU) Medical Device Regulation 2017/745, commonly referred to as EU MDR. The Zenix monitor/defibrillator is a groundbreaking device that redefines efficiency, clarity, and intelligence in both EMS and hospital settings. Built from years of feedback from customers, Zenix combines intuitive design with powerful functionality to enhance patient care and automate workflows for ease-of-use. Featuring a large, durable touchscreen, Zenix provides critical information when it’s needed. With on-the-fly customization, healthcare professionals can make real-time adjustments, helping them stay in control during high-pressure situations. Equipped with ZOLL’s innovative Real BVM Help® and exclusive Real CPR Help® technology, Zenix gives healthcare pro

Expereo Elevates expereoOne with New Digital Case Management Capabilities, Delivering Faster, Clearer and More Predictable Service Resolution10.2.2026 10:00:00 CET | Press release

Expereo is redefining what’s possible for global enterprises at CiscoLive Amsterdam with the launch of its enhanced Digital Case Management (DCM) capability in expereoOne. As the world-leading managed Network as a Service (NaaS) provider, Expereo is putting customers firmly in control - slashing resolution times, cutting through operational noise and ensuring everyone is aligned every step of the way. With DCM, service issues are no longer bottlenecks: instead, enterprises experience swift, transparent outcomes, with every stakeholder empowered through a single, real-time view of progress. DCM is designed around a simple objective: enable enterprises to resolve issues faster, with greater clarity and full control, through a fully digital, software-first workflow inside expereoOne. Customers can create, manage and track cases end-to-end within a single platform, ensuring predictable, consistent and aligned service experiences across their global network footprint. Unified, digital-first

U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 110.2.2026 09:15:00 CET | Press release

This FDA Acceptance is a Milestone for People Living with Narcolepsy Type 1 Who Need New and Different Treatment OptionsOveporexton is an Orexin Agonist Designed to Restore Orexin Signaling and Address the Underlying Orexin Deficiency that Causes Narcolepsy Type 1The Prescription Drug User Fee Act (PDUFA) Target Action Date is the Third Quarter of this Calendar Year Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) and granted Priority Review for oveporexton (TAK-861) for the treatment of narcolepsy type 1 (NT1). Oveporexton is an investigational oral orexin receptor 2 (OX2R)-selective agonist designed to address the underlying orexin deficiency that causes NT1 by restoring orexin signaling. The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date in the third quarter of this calendar year. Takeda remains on track to potentially bring the first approved orexin agonist treatment to people living

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye